The results showed that the FGF-2 level was significantly lower in patients with COPD AE compared to those without (4.5 vs. 12.4 pg/mL; p = 0.041), while the values of the remaining 10 growth markers did not significantly differ between the two groups (p > 0.05). This evidence concerns the gene FGF2 and chronic obstructive pulmonary disease.